Table 5.
% of patients | Study 1 (HEC) | Study 2 (AC) | Study 3 (non-AC MEC/HEC) | |||
---|---|---|---|---|---|---|
Time period | ≥65 yrs (N = 20) |
Overall population (N = 135) |
≥65 yrs (N = 116) |
Overall population (N = 724) |
≥65 yrs (N = 78) |
Overall population (N = 309) |
Acute (0–24 h) | 100 | 98.5 | 94.0 | 88.4 | 97.4 | 92.9 |
Delayed (25–120 h) | 100 | 90.4 | 81.0 | 76.9 | 80.8 | 83.2 |
Overall (0–120 h) | 100 | 89.6 | 79.3 | 74.3 | 78.2 | 80.6 |
HEC: highly emetogenic chemotherapy; AC: anthracycline cyclophosphamide; MEC: moderately emetogenic chemotherapy.